{
    "clinical_study": {
        "@rank": "60215", 
        "arm_group": [
            {
                "arm_group_label": "GLU_ASP", 
                "arm_group_type": "Experimental", 
                "description": "Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.\nFirst day: insulin glulisine\nSecond day: insulin aspart"
            }, 
            {
                "arm_group_label": "ASP_GLU", 
                "arm_group_type": "Experimental", 
                "description": "Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.\nFirst day: insulin aspart\nSecond day: insulin glulisine"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to determine whether insulin glulisine is more effective in\n      postprandial glycemic control than insulin aspart after the H-GI meal in children with type\n      1 diabetes (T1DM) treated with insulin pump (CSII)."
        }, 
        "brief_title": "Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "Some studies have suggested that insulin glulisine (GLU) has a slightly faster onset of\n      action compared with insulin aspart (ASP). Meals of high glycemic index (H-GI) have distinct\n      effect on postprandial glycaemia (PPG)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus\n\n          -  CSII for at least 3 months\n\n          -  Duration of diabetes > 1 years\n\n          -  Informed consent\n\n        Exclusion Criteria:\n\n          -  Concomitant dietary restrictions (e.g. celiac disease or food allergy)\n\n          -  Diabetes related complications\n\n          -  Baseline hyperglycemia >150 mg/dl\n\n          -  Any disease judged by the investigator to affect the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678235", 
            "org_study_id": "Glulisine_Aspart"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "GLU_ASP", 
                    "ASP_GLU"
                ], 
                "intervention_name": "Insulin glulisine", 
                "intervention_type": "Drug", 
                "other_name": "Apidra\u00ae"
            }, 
            {
                "arm_group_label": [
                    "GLU_ASP", 
                    "ASP_GLU"
                ], 
                "intervention_name": "Insulin aspart", 
                "intervention_type": "Drug", 
                "other_name": "NovoRapid\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin glulisine", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "diabetes", 
            "insulin pump", 
            "glulisine", 
            "aspart", 
            "glycemic index"
        ], 
        "lastchanged_date": "September 3, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Warsaw", 
                    "country": "Poland", 
                    "zip": "01-184"
                }, 
                "name": "Department of Pediatrics, Medical University of Warsaw, Poland"
            }, 
            "investigator": {
                "last_name": "Katarzyna D\u017cyga\u0142o, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Impact Of Insulin Glulisine In Comparison With Aspart On Postprandial Glycemia After The High-Glycemic Index Meal In Children With Type 1 Diabetes - Cross-Over Double-Blind, Randomized Clinical Trial.", 
        "other_outcome": {
            "measure": "Questionnaire: Glycemic Index Knowledge", 
            "safety_issue": "No", 
            "time_frame": "each subject was asked to fullfill the questionnaire before entering the study (day one)"
        }, 
        "overall_contact": {
            "email": "k.dzygalo@gmail.com", 
            "last_name": "Katarzyna D\u017cyga\u0142o, MD", 
            "phone": "+48224523284"
        }, 
        "overall_contact_backup": {
            "email": "agnieszka.szypowska@gmail.com", 
            "last_name": "Agnieszka Szypowska, A. Professor", 
            "phone": "+48224523284"
        }, 
        "overall_official": {
            "affiliation": "Department of Pediatrics, Medical University of Warsaw, Poland", 
            "last_name": "Katarzyna D\u017cyga\u0142o, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Postprandial glycemia", 
            "safety_issue": "Yes", 
            "time_frame": "baseline, 30, 60, 90, 120 and 180 minutes after the breakfast"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678235"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hypoglycemia was defined as a PG concentration below 60 mg/dl with or without symptoms", 
                "measure": "Hypoglycemia episodes", 
                "safety_issue": "Yes", 
                "time_frame": "3-h study period"
            }, 
            {
                "description": "based on continuous glucose monitoring system", 
                "measure": "Glucose Area Under the Curve (AUC)", 
                "safety_issue": "Yes", 
                "time_frame": "3-h study period"
            }, 
            {
                "measure": "Mean amplitude of glycemic excursion (MAGE)", 
                "safety_issue": "Yes", 
                "time_frame": "3-h study period"
            }, 
            {
                "measure": "Difference between the maximum and baseline glycemia", 
                "safety_issue": "Yes", 
                "time_frame": "3-h study period"
            }
        ], 
        "source": "Medical University of Warsaw", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Warsaw", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}